Argus raised their target price on shares of Actavis plc Ordinary Shares (NYSE:ACT) from $198.00 to $225.00 in a research note issued on Tuesday, Analyst Ratings Network reports. Argus’ price objective indicates a potential downside of 0.99% from the company’s current price. Actavis plc Ordinary Shares (NYSE:ACT) stock opened at $210.31 in last session, and closed at $212.38, while the day range of ACT stock is $207.50-$213.29.The stock showed a neagtive weekly performance of -5.42%.
Mylan, Inc. (NASDAQ: MYL) confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer’s (NYSE: PFE) Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Mylan Inc (NASDAQ:MYL) stock opened at $53.49, in last session and closed at $53.06, by loosed -1.72%. The 52 week range was $27.66-$57.52.Company’s market capitalization is $19.73 billion.
Commenting about the strong beginning to the year, Avanir Pharmaceuticals Inc (NASDAQ:AVNR) President and CEO Keith A. Katkin has been quoted to have said that, “The first quarter of fiscal 2014 was another strong quarter for Avanir building upon the breakout year that was 2013. At the start of 2013, we laid out a vision to build Avanir into a leading CNS company, and that vision had three key pillars which we’ve made significant progress on in the first quarter of 2014. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) stock loosed -3.10% and finished the last session at $4.06. The EPS of the stock remained -0.51. Company’s market capitalization is $618.32 million.
Zacks reaffirmed their neutral rating on shares of Zoetis (NYSE:ZTS) in a report issued on Wednesday, American Banking and Market News reports. They currently have a $31.00 target price on the stock. Zoetis Inc (NYSE:ZTS) stock opened the session at $30.07, and closed the session at $29.70. The 52 week range of the ZTS stock remained $28.77-$35.42 and the day range was $29.65-$30.24.
Leave a Reply